CATALYST PHARMACEUTICALS INC (CPRX)

Company Profile

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company is headquartered in Coral Gables, Florida and currently employs 82 full-time employees. The company went IPO on 2006-11-08. The firm is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The firm's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The firm's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The firm also has FYCOMPA (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older.

Company Info

CATALYST PHARMACEUTICALS INC

355 Alhambra Circle, Suite 801

Coral Gables FLORIDA 33134

P: 13055292522

CEO: Patrick J. McEnany

Employees: 82

Website: https://catalystpharma.com/